Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 621 to 630 of 2432 total matches.
Dapagliflozin/Saxagliptin (Qtern) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018 (Issue 1543)
with extended-release metformin
(Xigduo XR; Kombiglyze XR).1 Three SGLT2/DPP-4
inhibitor combinations are now ...
The FDA has approved Qtern (AstraZeneca), a
fixed-dose combination of the sodium-glucose
co-transporter 2 (SGLT2) inhibitor dapagliflozin
(Farxiga) and the dipeptidyl peptidase-4 (DPP-4)
inhibitor saxagliptin (Onglyza), for oral treatment
of adults with type 2 diabetes. Dapagliflozin and
saxagliptin have each been available for years alone
and in combination with extended-release metformin
(Xigduo XR; Kombiglyze XR). Three SGLT2/DPP-4
inhibitor combinations are now available in the US
(see Table 2).
In Brief: Two New Drugs for AML (online only)
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018 (Issue 1543)
in increased efficacy in animal
studies.1 In a trial in 309 patients 60-75 years old with these
subtypes ...
The FDA has approved two new drugs for treatment of specific subtypes of acute myeloid leukemia (AML).Vyxeos (Jazz Pharmaceuticals) is a liposomal fixed-dose combination of daunorubicin and cytarabine, the standard drugs used for induction treatment of AML. It is approved for induction and consolidation treatment in adults with newly diagnosed chemotherapy- or radiation-related AML or AML with myelodysplasia-related changes. Patients with these subtypes of AML have a poor prognosis. The rationale for development of the combination was that nano-scale liposomal drug delivery vehicles prolong...
Comparison Table: Some Systemic Fluoroquinolones (online only)
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018 (Issue 1543)
/min/1.73
m2: 200 mg IV q12h; no
adjustment needed for
oral formulation
eGFR ...
View the Comparison Table: Some Systemic Fluoroquinolones (online only)
Comparison Table: Some Antibiotics for MRSA Skin and Skin Structure Infections (online only)
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018 (Issue 1543)
, then 500 mg 1 week later
Infuse over 30 minutes
CrCl ...
View the Comparison Table: Some Antibiotics for MRSA Skin and Skin Structure Infections
Odactra - Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Feb 26, 2018 (Issue 1541)
extracts were approved earlier (see Table 1).1
Pronunciation Key
Odactra: oh dac' trah
allergen ...
The FDA has approved Odactra (ALK), a sublingual
allergen extract, for immunotherapy in adults 18-65
years old with house dust mite (HDM)-induced allergic
rhinitis, with or without conjunctivitis. Odactra is the
first sublingual allergen extract to be approved in the
US for this indication. Three other sublingual allergen
extracts were approved earlier (see Table 1).
Benralizumab (Fasenra) for Severe Eosinophilic Asthma
The Medical Letter on Drugs and Therapeutics • Feb 26, 2018 (Issue 1541)
;
mepolizumab (Nucala) and reslizumab (Cinqair), which
target IL-5 itself, were approved earlier.1 ...
The FDA has approved benralizumab (Fasenra –
AstraZeneca), a humanized monoclonal antibody
selective for the interleukin-5 (IL-5) receptor, for
add-on maintenance treatment of severe asthma in
patients ≥12 years old with an eosinophilic phenotype.
Benralizumab is the third anti-IL-5 antibody to be
approved for treatment of severe eosinophilic asthma;
mepolizumab (Nucala) and reslizumab (Cinqair), which
target IL-5 itself, were approved earlier.
Once-Monthly Subcutaneous Buprenorphine (Sublocade) for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Feb 26, 2018 (Issue 1541)
opioid use disorder.1 Sublocade is the first injectable
buprenorphine product to be approved ...
The FDA has approved a subcutaneous (SC)
extended-release formulation of the mu-opioid
receptor partial agonist and kappa-opioid receptor
antagonist buprenorphine (Sublocade – Indivior)
for once-monthly treatment of moderate to severe
opioid use disorder. Sublocade is the first injectable
buprenorphine product to be approved in the US.
Buprenorphine is also available in sublingual
formulations with or without the opioid antagonist
naloxone, in a buccal formulation with naloxone, and
as a subdermal implant (Probuphine).
Haegarda - A Subcutaneous C1 Esterase Inhibitor for Prevention of Hereditary Angioedema
The Medical Letter on Drugs and Therapeutics • Feb 26, 2018 (Issue 1541)
THE DISEASE — HAE, an autosomal dominant disorder
with an estimated prevalence of 1:10,000-50,000 ...
The FDA has approved Haegarda (CSL Bering), a
human plasma-derived C1 esterase inhibitor (C1INH),
for prophylaxis against hereditary angioedema (HAE)
attacks in adolescents and adults. Haegarda is the
fourth C1INH to be approved by the FDA and the
second to be approved for HAE prophylaxis. Unlike
the other C1INHs, Haegarda is self-administered
subcutaneously rather than intravenously.
A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B)
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018 (Issue 1539)
hepatitis B component as Engerix-B
and is licensed for use only in adults. 1
Table 1. Hepatitis B Vaccines ...
The FDA has approved a two-dose hepatitis B virus
(HBV) vaccine (Heplisav-B – Dynavax) for use in adults
≥18 years old. The three other HBV vaccines marketed
in the US are usually administered in 3 doses. Engerix-B
and Recombivax HB are licensed for use in persons of
all ages. A combination hepatitis A/B vaccine (Twinrix)
contains the same hepatitis B component as Engerix-B
and is licensed for use only in adults.
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018 (Issue 1539)
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes ...
The FDA has approved semaglutide (Ozempic – Novo
Nordisk), a long-acting injectable GLP-1 (glucagon-like
peptide-1) receptor agonist, for once-weekly
treatment of adults with type 2 diabetes. It is the sixth
GLP-1 receptor agonist to be approved in the US.